BioAge
在场
BioAge 是一家在股票代码 BIOA (US) 下上市的公司。
涉及BioAge的并购和融资。
- BioAge现以股票代码BIOA上市。 (公布2024十月3号).
- BioAge 刚刚宣布为 198 筹款数百万美元。 (公布2024十月3号).
- BioAge 刚刚宣布为 170 筹款数百万美元。 (公布2024二月20号).
高管
查看带有其 20 名主要高管的组织结构图
BioAge 搜索最多的简介
- Kristen Fortney, Chief Executive Officer and Director
- James Healy, Director
- Jean-Pierre Garnier, Chairman of the Board
高管在BioAge变化
- James Healy 曾任 Chairman of the Board, 现任 Director (新闻发布的2024八月22号).
- Jean-Pierre Garnier已作为Chairman of the Board加入公司 (新闻发布的2024八月22号).
- Michael Davidson已作为Director加入公司 (新闻发布的2024四月12号).
创建提醒
跟踪 BioAge 的高管变动
生物技术
BioAge 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
BioAge 的最新新闻稿
- BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
- BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
- BioAge Labs to Present at Upcoming Investor Conferences
- BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
- BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
- BioAge Labs to Present at Jefferies London Healthcare Conference
- BioAge Labs Announces Pricing of Upsized Initial Public Offering
- BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement | Tue, 10/01/2024 - 16:30
- BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
- BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
- View more press releases Close
关于 BioAge 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Kristen Fortney 
